Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and CancerInsights From Large Randomized Statin Trials
Alawi A. Alsheikh-Ali, MD,
Prasad V. Maddukuri, MD,
Hui Han, MD and
Richard H. Karas, MD, PhD1,*
Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Relationship Between Rates of Elevated Liver Enzymes and % LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treatment arms (i.e., number of patients in each arm). LDL-C = low-density lipoprotein cholesterol.
|
|
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Relationship Between Rates of Rhabdomyolysis and % LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treatment arms (i.e., number of patients in each arm). LDL-C = low-density lipoprotein cholesterol.
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Rate of Elevated Liver Enzymes by Statin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduction in low-density lipoprotein cholesterol (LDL-C) for the following statin dose categories: low dose (lovastatin 20 mg, simvastatin 20 mg, and atorvastatin 10 mg), intermediate dose (lovastatin 40 mg, simvastatin 40 mg, and pravastatin 40 mg), and high dose (lovastatin 80 mg, simvastatin 80 mg, fluvastatin 80 mg, and atorvastatin 80 mg).
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Rate of Elevated Liver Enzymes by Lovastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduction in low-density lipoprotein cholesterol (LDL-C) for low-dose (20 mg), intermediate-dose (40 mg), and high-dose (80 mg) lovastatin.
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Rate of Elevated Liver Enzymes by Simvastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduction in low-density lipoprotein cholesterol (LDL-C) for low-dose (20 mg), intermediate-dose (40 mg), and high-dose (80 mg) simvastatin.
|
|
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 6 Rate of Elevated Liver Enzymes by Atorvastatin Dose Category
Rate of elevated liver enzymes per 100,000 person-years for each 10% reduction in low-density lipoprotein cholesterol (LDL-C) for low-dose (10 mg) and high-dose (80 mg) atorvastatin.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 7 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and % LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treatment arms (i.e., number of patients in each arm). BID = twice daily; LDL-C = low-density lipoprotein-cholesterol; QD = once daily. See text for trial acronym definitions.
|
|
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 8 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Absolute LDL-C Reduction
The sizes of the open circles represent the relative sizes of the statin treatment arms (i.e., number of patients in each arm). Abbreviations as in Figure 7.
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 9 Relationship Between Rates of Newly Diagnosed Cancer per 100,000 Person-Years and Achieved LDL-C Level
The sizes of the open circles represent the relative sizes of the statin treatment arms (i.e., number of patients in each arm). Abbreviations as in Figure 7.
|
|
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 10 Rate of Newly Diagnosed Cancer by Statin Dose Category
Rate of newly diagnosed cancer per 100,000 person-years for each 10% reduction in low-density lipoprotein-cholesterol (LDL-C) for the following statin dose categories: low dose (lovastatin 20 mg), intermediate dose (lovastatin 40 mg, simvastatin 40 mg, and pravastatin 40 mg), and high dose (lovastatin 80 mg, fluvastatin 80 mg).
|
|
|
